Press Release

MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics (“ASC”), a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced today that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences (“Vigene”), a Maryland-based Contract Develop and Manufacturing Organization (CDMO). Vigene will provide ASC with access to GMP manufacturing including viral vectors … Read more

5/16/19 MILPITAS, Calif.–(BUSINESS WIRE) — ASC Therapeutics, A Division of Applied StemCell, Inc. (ASC), announced today that it has obtained an exclusive therapeutics license from Expression Therapeutics, LLC (ET) for coagulation factor VIII expression technologies including a highly compact, yet potent, liver-directed promoter and matching liver-codon optimized factor VIII transgene for adeno-associated viral vector gene therapy … Read more

4/25/19 MILPITAS, Calif.–(BUSINESS WIRE)– Applied StemCell, Inc. (ASC), a leading gene-editing company, announced that its therapeutic division (ASC Therapeutics) has cured Hemophilia A in mice and will be presenting their in vivo and in vitro findings at the 22nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held April 29 – May 2 in Washington D.C. ASC … Read more